AniMeloxan 1.5mg/ml Oral Suspension
Country: United Kingdom
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
14-09-2013
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
meloxicam 1.25 mg
Available from:
aniMedica GmbH
ATC code:
QM01AC06
Pharmaceutical form:
Suspension for injection
Therapeutic group:
meloxicam
Therapeutic area:
Dogs
Authorization date:
2009-10-22
Summary of Product characteristics
Revised: September 2013
AN. 01030/2012
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Animeloxan 1.5 mg/ml oral suspension for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of suspension contains:
Active substance:
Meloxicam 1.5 mg (equivalent to 0.05 mg per drop)
Excipient:
Sodium benzoate 1.5 mg (equivalent to 0.05 mg per drop)
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension
The product is a pale yellow viscous suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal
disorders.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in dogs less than 6 weeks of age.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
Revised: September 2013
AN. 01030/2012
Page 2 of 6
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of increased renal toxicity.
In case of prolonged use, monitoring durin
Read the complete document
